These sales are too small in both absolute and relative terms to convey any bearish signal. They are likely routine portfolio diversification or tax-related transactions. Monitor for any larger insider purchases or material changes in insider ownership percentages in future Form 4 filings.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 18 $19.80entry
- T+1 · 5mo ago +5.40%α +5.72% · $20.87
- T+5 · 5mo ago +4.09%α +5.76% · $20.61
- T+20 · 4mo ago +14.75%α +14.21% · $22.72
- T+60 · 2mo ago −6.46%α −8.36% · $18.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three top executives (CEO, CMO, CCO) at Dyne Therapeutics sold a combined ~$68K in shares on June 16, 2026, the same day the company announced a $50M draw on its expanded $400M Hercules Capital debt facility. The dollar amount is negligible, ~0.002% of the company's $3.0B market cap, making this a routine, non-informative insider sale cluster with no actionable signal.
Key Financial Metrics
Key Facts
- CEO John Cox sold 2,683 shares for ~$49K at $18.33/share on June 16.
- CMO Douglas Kerr sold 887 shares for ~$16K at $18.33/share.
- CCO Johanna Friedl-Naderer sold 145 shares for ~$3K at $18.33/share.
- Total insider sales of $68K represent ~0.0023% of DYN's $3.0B market cap.
- The sales occurred on the same day as a $50M draw under the company's expanded credit facility (8-K filed June 17).
Financial Impact
Negligible, total insider sales of ~$68K, less than 0.01% of market cap.
Risk Factors
- Dilution risk from the expanded debt facility's conversion features (if any).
- Possible future insider selling if executives accelerate liquidation ahead of data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DYN-1781727045957 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers